SARS-CoV-2 IgG/IgM Rapid Test Kit |
|
abx294171-100g |
Abbexa |
100 µg |
EUR 1525 |
Human IgG antibody Laboratories manufactures the sars cov 1 antibody test results reagents distributed by Genprice. The Sars Cov 1 Antibody Test Results reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact SARS Antibody. Other Sars products are available in stock. Specificity: Sars Category: Cov Group: 1 Antibody
Human IgG Quick test strip |
|
MyBiosource |
5x10Tests |
EUR 1180 |
COX (Coxsackievirus Antibody IgG) ELISA test |
|
Biobase |
96T/Box |
Ask for price |
|
|
|
Description: ELISA based test for quantitative detection of COX (Coxsackievirus Antibody IgG) |
Monoclonal antibody to human IgG for rapid test |
|
MyBiosource |
1mg |
EUR 480 |
Monoclonal antibody to human IgG for rapid test |
|
MyBiosource |
2mg |
EUR 700 |
Monoclonal antibody to human IgG for rapid test |
|
MyBiosource |
5mg |
EUR 1505 |
Typhoid IgG and IgM (S. typhi IgG + IgM) Rapid Test Kit |
|
Abbexa |
100 µl |
EUR 650 |
1 Antibody information
TruStrip RDT Sulfonamides residues (SAs) rapid test strips, results is 2-10 mins, 50 strips/pk |
|
DE-100090-RDT |
Alpha Diagnostics |
1 pk |
EUR 781.2 |
TruStrip RDT Beta-Lactam and Tetracyclines rapid test strips, results is 2-10 mins, 50 strips/pk |
|
DE-100260-RDT |
Alpha Diagnostics |
1 pk |
Ask for price |
TruStrip RDT Canine distemper virus (hardpad disease) antigen rapid test card, results is 2-10 mins, 50 cards/pk |
|
RV-501200-RDT |
Alpha Diagnostics |
1 pk |
Ask for price |
TruStrip RDT Humanized Ebola IgG (humanized IgGs expressed in tobacco or other plants) rapid test (results in 2-10 min), 25 cassettes/pk |
|
AE-320880-RDT-25 |
Alpha Diagnostics |
1 pk |
EUR 351.6 |
SARS-CoV-2-Spike Antibody Rapid Test Kit |
|
abx090710-100l |
Abbexa |
100 µl |
EUR 650 |
SARS-CoV-2-Spike Antibody Rapid Test Kit |
|
abx090710-1ml |
Abbexa |
1 ml |
EUR 10500 |
SARS-CoV-2-Spike Antibody Rapid Test Kit |
|
abx090710-200l |
Abbexa |
200 µl |
EUR 2100 |
SARS-CoV-2 Neutralization Antibody Rapid Test Kit |
|
abx092242-100l |
Abbexa |
100 µl |
EUR 1925 |
SARS-CoV-2 Neutralization Antibody Rapid Test Kit |
|
abx092242-1ml |
Abbexa |
1 ml |
EUR 22500 |
SARS-CoV-2 Neutralization Antibody Rapid Test Kit |
|
abx092242-200l |
Abbexa |
200 µl |
EUR 6600 |
Multiple organs tumor tissue array, including pathology grade, TNM, clinical stage IHC markers (ER, PR, Her-2) results, 118 cases/208 cores |
|
BR20838 |
BioCoreUSA |
row: 13; column: 16; cores: 208; cases: 118 |
EUR 474 |
|
Description: Multiple organs tumor tissue microarray, containing 80 cases of breast invasive carcinoma of no special type, 10 cancer adjacent breast tissue, duplicate cores per case, 4 ovary serous adenocarcinoma, 4 uterus endometrioid adenocarcinoma, 6 rectum adenocarcinoma, 6 colon adenocarcinoma, 2 esophagus squamous cell carcinoma, 2 stomach carcinoma, 2 pancreas adenocarcinoma, 2 lung carcinoma, single core per case |
anti- SARS antibody |
|
FNab07609 |
FN Test |
100µg |
EUR 658.5 |
|
|
|
Description: Antibody raised against SARS |
Breast tumor tissue array (18 of 25), including pathology grade, TNM, clinical stage and IHC markers (ER, PR, Her-2) results,104 cases/208 cores |
|
BR20824 |
BioCoreUSA |
row: 13; column: 16; cores: 208; cases: 104 |
EUR 474 |
|
Description: Breast tumor tissue microarray (slide 18 of 2600 cases of breast cancer survey slide set), containing 83 cases of invasive carcinoma of no special type, 4 mucinous carcinoma, 9 medullary carcinoma, 6 invasive lobular carcinoma, 1 each of apocrine carcinoma and cystosarcoma phyllodes, duplicate cores per case |
SARS-CoV-2 Ag Rapid Test |
|
HSGIA2200A1COV |
Hi-Senty |
20 Tests/Kit |
Ask for price |
|
Description: The SARS-CoV-2 Ag Rapid Test is a rapid chromatographic immunoassay for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigens in nasal swab specimens from individualswith suspected SARS-CoV-2 infection in conjunction with clinical presentation and the results of other laboratory tests. Results are for the detection of SARS-CoV-2 Antigens. An antigen is generally detectable in upper respiratory specimens during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or coinfection with other viruses. The agent detected may not be the definite cause of disease. Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions. Negative results should be treated as presumptive and confirmed with a molecular assay, if necessary for patient management. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19. The SARS-CoV-2 Ag Rapid Test is intended for use by self-testing personnel. |